Mektovi (binimetinib) — Medica
melanoma
Initial criteria
- age ≥ 18 years
- unresectable, advanced, or metastatic melanoma
- EITHER: (a) BRAF V600 mutation-positive disease AND used in combination with Braftovi (encorafenib); OR (b) NRAS mutation AND has tried at least one immune checkpoint inhibitor therapy
Approval duration
1 year